title: Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model.
abstract: Animal models facilitate evaluation of vaccine efficacy at relatively low cost. This study was a comparative evaluation of the immunogenicity and protective efficacy of a new 13-valent pneumococcal conjugate vaccine (PCV13) with a control vaccine in a mouse model. After vaccination, anti-capsular antibody levels were evaluated by pneumococcal polysaccharide (PnP) enzyme-linked immunosorbent assay (ELISA) and opsonophagocytic killing assay (OPA). Also, mice were challenged intraperitoneally with 100-fold of the 50% lethal dose of Streptococcus pneumoniae. The anti-capsular IgG levels against serotypes 1, 4, 7F, 14, 18C, 19A, and 19F were high (quartile 2 >1,600), while those against the other serotypes were low (Q2 ≤ 800). Also, the OPA titres were similar to those determined by PnP ELISA. Comparative analysis between new PCV13 and control vaccination group in a mouse model exhibited significant differences in serological immunity of a few serotypes and the range of anti-capsular IgG in the population. Challenge of wild-type or neutropenic mice with serotypes 3, 5, 6A, 6B, and 9V showed protective immunity despite of induced relatively low levels of anti-capsular antibodies. With comparison analysis, a mouse model should be adequate for evaluating serological efficacy and difference in the population level as preclinical trial.
authors.affiliation: a Vaccine Bio Research Institute , College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.
authors.forename: Chulmin
authors.initials: C
authors.lastname: Park
authors.affiliation: a Vaccine Bio Research Institute , College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.
authors.forename: Eun-Young
authors.initials: EY
authors.lastname: Kwon
authors.affiliation: b Division of Infectious Diseases , Department of Internal Medicine, College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.
authors.forename: Su-Mi
authors.initials: SM
authors.lastname: Choi
authors.affiliation: a Vaccine Bio Research Institute , College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.|b Division of Infectious Diseases , Department of Internal Medicine, College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.
authors.forename: Sung-Yeon
authors.initials: SY
authors.lastname: Cho
authors.affiliation: a Vaccine Bio Research Institute , College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.
authors.forename: Ji-Hyun
authors.initials: JH
authors.lastname: Byun
authors.affiliation: a Vaccine Bio Research Institute , College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.
authors.forename: Jung Yeon
authors.initials: JY
authors.lastname: Park
authors.affiliation: a Vaccine Bio Research Institute , College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.|b Division of Infectious Diseases , Department of Internal Medicine, College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.
authors.forename: Dong-Gun
authors.initials: DG
authors.lastname: Lee
authors.affiliation: a Vaccine Bio Research Institute , College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.|c Department of Pediatrics , College of Medicine, The Catholic University of Korea , Seoul , the Republic of Korea.
authors.forename: Jin Han
authors.initials: JH
authors.lastname: Kang
authors.affiliation: d School of Pharmacy , Sungkyunkwan University , Suwon , the Republic of Korea.|e SK Chemicals Co. Ltd ., Seongnam , Gynuggi-do , the Republic of Korea.
authors.forename: Jinhwan
authors.initials: J
authors.lastname: Shin
authors.affiliation: e SK Chemicals Co. Ltd ., Seongnam , Gynuggi-do , the Republic of Korea.
authors.forename: Hun
authors.initials: H
authors.lastname: Kim
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial; D016667:Bacterial Capsules / Q000276:immunology; D004195:Disease Models, Animal; D000071497:Immunogenicity, Vaccine; D007074:Immunoglobulin G / Q000097:blood; D051379:Mice; D009503:Neutropenia; D009895:Opsonin Proteins; D010587:Phagocytosis; D011008:Pneumococcal Infections / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology; D065288:Serogroup; D013296:Streptococcus pneumoniae / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: C538862:13-valent pneumococcal vaccine; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D009895:Opsonin Proteins; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate
keywords: Mouse model; Neutropenic infection model; Streptococcus pneumoniae; pneumococcal conjugate vaccine; protection efficacy; serological evaluation